SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Moderna, Inc. engages in the development of transformative medicines based on messenger ribonucleic acid. The firm's product pipeline includes the following modalities: prophylactic vaccines, cancer vaccines, intratumoral immuno-oncology, localized regenerative therapeutics, systemic secreted therapeutics, inhaled pulmonary therapeutics and systemic intracellular therapeutics. It operates through the following geographical segments: United States, Europe, and Rest of World. The company was founded by Noubar B. Afeyan, Robert S. Langer, Jr., Derrick J. Rossi, and Kenneth R. Chien in 2010 and is headquartered in Cambridge, MA.

Moderna Inc

An alleged early leak of Phase 3 results for Moderna and Mercks personalized melanoma vaccine triggered a sharp selloff ahead of the full data presentation. Traders disagree over whether the reported benefit is clinically meaningful but fell short of elevated expectations, and some question the leaks accuracy while others expect more volatility around the full readout.

Space Exploration Technologies Corp., doing business as SpaceX, operates as an aerospace manufacturer, launch service provider, and satellite communications company. It is building the integrated hardware and software infrastructure of the future across space, connectivity, and AI. The firm designs, manufactures, launches, and operates products and services built on cutting-edge technologies, including the rockets and spacecraft. The company was founded by Elon Reeve Musk in 2002 and is headquartered in Starbase, TX.

Space Exploration Technologies Corp. - Ordinary Shares - Class A

SpaceX

SPCXs sharp pullback after its earnings-driven jump is being attributed mainly to a large share unlock that traders fear will add selling pressure, alongside broader tech weakness and concerns about heavy spending and a possible Tesla tie-up. The earnings beat has not eased the bearish reaction, though some investors view the decline as a buying opportunity.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

A sharp selloff in semiconductor and technology stocks has pushed SOXL to a six-month low, with its 3x daily leverage amplifying the decline. Traders are split between seeing AI-funding concerns and broader market pressure as signs of further downside, and treating the drop as an oversold buying opportunity.

Invesco QQQ Trust Series 1 - Invesco QQQ Trust Series 1

QQQ is drawing attention amid a sharp tech-led selloff, with traders focused on worries about AI spending and credit availability, weakness in semiconductors, and elevated oil prices tied to Iran tensions. The conversation is largely bearish, though some traders see an oversold dip-buying opportunity or expect a rebound.

Amazon.com, Inc. is a multinational technology company, which engages in the provision of online retail shopping services. It operates through the following segments: North America, International, and Amazon Web Services (AWS). The North America segment offers retail sale of consumer products, including from sellers, advertising, and subscriptions services through North America-focused online and physical stores. The International segment focuses on retail sale of consumer products, including sellers, advertising, and subscription services through internationally focused online stores. The AWS segment is composed of global sales of computers, storage, databases, and other services for start-ups, enterprises, government agencies, and academic institutions. The company was founded by Jeffrey P. Bezos in July 1994 and is headquartered in Seattle, WA.

Amazon.com Inc.

Amazon.com Inc

AMZNs sharp decline is being discussed largely alongside selling across mega-cap tech and hyperscalers, with traders also questioning whether heavy AI and data-center spending could pressure cash flow ahead of earnings. Reactions are split between dip buyers calling the drop excessive and bearish traders anticipating further weakness; no single confirmed company-specific catalyst dominates.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokias Q3 results beat expectations and AI/cloud demand surged, but shares sold off sharply as traders focused on negative free cash flow, a lower cash-conversion outlook, higher restructuring costs and supply-chain cost pressure. Bulls call the reaction an overreaction and point to AI and network growth, while bears argue cash generation and the outlook matter more than the headline beat.

Meta Platforms, Inc. engages in the development of social media applications. It builds technology that helps people connect and share, find communities, and grow businesses. It operates through the Family of Apps (FoA) and Reality Labs (RL) segments. The FoA segment consists of Facebook, Instagram, Messenger, WhatsApp, and other services. The RL segment includes augmented, mixed and virtual reality related consumer hardware, software, and content. The company was founded by Mark Elliot Zuckerberg, Dustin Moskovitz, Chris R. Hughes, Andrew McCollum, and Eduardo P. Saverin on February 4, 2004, and is headquartered in Menlo Park, CA.

Meta Platforms Inc - Ordinary Shares - Class A

Meta Platforms Inc

Metas sharp selloff after its quarterly results is being linked to rising AI infrastructure spending, negative free cash flow, and concerns that the new nonvoting share class could enable future fundraising and dilute shareholders, despite strong advertising performance and upbeat guidance. Traders are split between viewing the drop as a buying opportunity and questioning whether AI investments can generate enough returns to justify the costs.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968, and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is drawing attention after a sharp month-long slide amid weakness across semiconductor and AI stocks, with traders also focused on its test of the 200-day moving average and upcoming earnings. Some view the selloff as an oversold buying opportunity near support, while others warn that the decline could continue; the cause is not settled in the discussion.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMD is caught in a sharp semiconductor and tech selloff, alongside broader Nasdaq weakness, as traders debate stretched AI valuations, data-center spending returns, and macro risks. Some see the decline as an oversold dip-buying opportunity ahead of earnings, while others warn of a deeper AI-sector correction.

Alphabet, Inc. is a holding company, which engages in software, health care, transportation, and other technologies. It operates through the following segments: Google Services, Google Cloud, and Other Bets. The Google Services segment includes products and services, such as ads, Android, Chrome, devices, Google Maps, Google Play, Search, and YouTube. The Google Cloud segment refers to infrastructure and platform services, collaboration tools, and other services for enterprise customers. The Other Bets segment relates to the sale of healthcare-related services and internet services. The company was founded by Lawrence E. Page and Sergey Mikhaylovich Brin on October 2, 2015 and is headquartered in Mountain View, CA.

Alphabet Inc - Ordinary Shares - Class A

Alphabet Inc Class A

Alphabet shares are under pressure amid a broader tech selloff and pre-earnings uncertainty, with traders focused on whether heavy AI and data-center spending will translate into returns. Some are buying the dip ahead of the report, while others fear rising capex and debt could weigh on results and guidance.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Revolution Medicines Begins Phase 3 Trial For Advanced Lung Cancer Treatment

Revolution Medicines doses first patients in its global Phase 3 trial testing zoldonrasib for metastatic non-small cell lung cancer.read more...

Revolution Medicines Stock Has Surged 124% This Year  Analyst Sees More Room to Grow

William Blair sets $226 price target for Revolution Medicines (RVMD) following Rasonque approval and major oncology expansion plans.read more...

VSTM Stock Clocks Best Day In 11 Months After Positive Cancer Drug Trial Update And Multiple Price-Target Hikes

Equity

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 


Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda

Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research Agenda Cancer Drug Spending Is Headed Past $400 Billion as Colorectal and Pancreatic Cancers Move Up the Research AgendaPR NewswireSAN DIEGO, Oct. 14, 2026SAN DIEGO, Oct. 14, 2026 /PRNewswire...

2026 Brings New Hope in the Fight Against Cancer as Breakthroughs Gather Momentum

NeOnc Technologies (NASDAQ:NTHI), Revolution Medicines (NASDAQ:RVMD), Moderna (NASDAQ:MRNA), Merck (NYSE:MRK), Johnson & Johnson (NYSE:JNJ), Genmab (NASDAQ:GMAB), and AbbVie (NYSE:ABBV) are among the companies contributing to a rapidly evolving cancer-treatment landscape in 2026, as researchers pursue new ways to extend survival, target tumors more precisely and give patients additional treatment options.

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034

KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034 KRAS Inhibitor Market Projected to Reach $7.8 Billion by 2034PR NewswireSAN DIEGO, Sept. 28, 2026 SAN DIEGO, Sept. 28, 2026 /PRNewswire/ -- Equity Insider News Commentary- For most of the last four decades, RAS was the target oncology...

Is Buying Royalty Pharma Stock a Safer Way to Bet on Revolution Medicines?

Key PointsRevolution Medicines has just received good news around a drug meant to treat pancreatic cancer...

Here's How Much $1000 Invested In Revolution Medicines 5 Years Ago Would Be Worth Today

Revolution Medicines (NASDAQ:RVMD) has outperformed the market over the past 5 years by 33.5% on an annualized basis producing an average annual return of 45.32%. Currently, Revolution Medicines has a marketread more...

Axsome Therapeutics vs. Revolution Medicines: Which Healthcare Stock Is a Better Buy in 2026?

Key PointsAxsome Therapeutics is generating rapid revenue growth through its expanding portfolio of commercialized central nervous system treatments...

Revolution Medicines Just Hit a Major Milestone. Is the Stock a Buy?

Key PointsRevolution Medicines validated its approach to treating certain cancers with a recent regulatory approval...

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Neutral Sentiment

<ul class="summary-bullets"><li>Alliance Global on Thursday raised its price target on VSTM to $22 from $18 and maintained a Buy rating.</li><li>RBC Capital analyst Leonid Timashev said that while VS-7375 tolerability is not as favorable as Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.&nbsp;</li><li>BTIG said VS-7375 could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.</li></ul> Shares of Verastem Oncology (VSTM) jumped 20% on Thursday, clocking its best day since Nov. 2025, as analysts lifted price targets following a positive update on the company’s experimental drug VS-7375 in second-line metastatic pancreatic ductal adenocarcinoma.On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose, along with responses in lung and colorectal cancers and a manageable safety profile dominated by low-grade gastrointestinal side effectsVerastem also added that the company has aligned with the U.S. Food and Drug Administration on a late-stage path in first-line metastatic pancreatic cancer using chemotherapy-free regimens, with the study expected to open by year-end.<h2 class="st-heading-2">Wall Street Weighs In On VSTM</h2>Alliance Global on Thursday subsequently raised its price target to $22 from $18 and maintained a Buy rating, describing the updated TARGET-D 101 data as showing a highly tolerable safety profile and efficacy that is in line with or better than other drugs in the same class and in development, potentially best-in-class.RBC Capital analyst Leonid Timashev increased the target to $19 from $14 while keeping an Outperform rating, calling the drug clearly active with hints of best-in-class efficacy in pancreatic ductal adenocarcinoma. He noted that while tolerability is not as favorable as one competitor, Revolution Medicines’ experimental drug Zoldonrasib, the overall profile remains acceptable.BTIG raised its target to $24 from $18 and kept a Buy rating, saying the detailed update across second-line pancreatic cancer, second-line non-small cell lung cancer, and third-line colorectal cancer points to class-leading efficacy that could rival Revolution Medicines’ approved drug Daraxonrasib in second-line metastatic pancreatic disease.Jefferies analyst Faisal Khurshid raised the price target to $13 from $11 and maintained a Buy rating. Aligning on a favorable late-stage trial path, he added, positions Verastem only about seven months behind competitors Revolution Medicines and Incyte in the race to develop drugs within the same class.<h2 class="st-heading-2">CEO Change And Capital Raising</h2>Verastem on Wednesday also priced a $250 million offering of common stock and pre-funded warrants at $8 per share to support VS-7375 development and general purposes, expected to close around October 15.The company further announced a planned CEO transition, with longtime executive Daniel Paterson retiring effective January 1, 2027, and board member Michael P. Bailey succeeding him.<h2 class="st-heading-2">How Did VSTM Retail Traders React?</h2>On Stocktwits, retail sentiment around VSTM stayed within ‘extremely bullish’ territory over the past 24 hours, while message volume stayed at ‘extremely high’ levels.“The more I watch it, the more constructive it looks,” a Stocktwits user wrote about the stock.<stembedurl>https://stocktwits.com/topstockalerts/message/666627602</stembedurl>Another user drew a parallel between VSTM’s current rally and Iovance Biotherapeutics Inc (IOVA) stock’s rally last month, which lasted for several days.<stembedurl>https://stocktwits.com/Always_neutral/message/666623781</stembedurl><a class="mention" data-mention="$VSTM" data-symbol-id="VSTM" href="https://stocktwits.com/symbol/VSTM" target="_blank">VSTM stock</a> has gained 2o% year-to-date.&nbsp;Read More: <a href="https://stocktwits.com/news-articles/markets/equity/mrna-stock-hits-fresh-52-week-highs-as-goldman-raises-target-ahead-of-melanoma-data/cZxh3NsRBrS">MRNA Stock Hits Fresh 52-Week Highs As Goldman Raises Target Ahead Of Melanoma Data</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Verastem Oncology logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

On Wednesday, Verastem said that in its ongoing early-stage TARGET-D 101 trial, VS-7375 produced a 50% confirmed overall response rate in second-line metastatic pancreatic ductal adenocarcinoma at the 900 mg daily dose. 

Incyte Corp.

Verastem Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Current Price	$186.35
Prev Close	$194.28
Open	$191.18
Dividend Yield	0.00%
50-Day Moving Average	$202.23
Beta	1.16
Avg. Volume	2.01M
PE Ratio	-22.04

52-Week High	$224.31
52-Week Low	$52.48
Market Capitalization	$41.64B
EPS (Annual)	-$5.95
Price to Book	15.97
Revenue Per Employee	$0.00

Feed

News

Sentiment

Earnings

Fundamentals

Info

RVMD Fundamentals